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A promoter polymorphism of the insulin-like growth factor-I
gene is associated with left ventricular hypertrophy
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eft ventricular hypertrophy (LVH) is a strong predictor of
cardiovascular morbidity and mortality. Insulin-like
growth factor-I (IGF-I) has an important role in the
hypertrophic response of the myocardium.1 A polymorphism
in the IGF-I gene promoter region has been identified which
influences IGF-I production.2–4 Studying this polymorphism
in relation to pathology may better reflect the effects of long
term IGF-I exposure than studies on serum IGF-I concentra-
tions, which may fluctuate considerably and are profoundly
influenced by various factors. We investigated the association
between this IGF-I promoter polymorphism and the occur-
rence of LVH on echocardiogram.
METHODS
The Rotterdam study is a population based cohort study in
7983 elderly people aged 55 years or over. The baseline
examination was conducted in 1990–93, during which time
information was obtained on age, sex, history of myocardial
infarction, smoking, hypertension, diabetes mellitus, and
body mass index (BMI). Cardiac ultrasound was performed
in a random subpopulation of 2823 subjects. The present
study was performed in subjects aged 55–75 years, without a
history of myocardial infarction. The analyses were restricted
to persons with an adequate echocardiogram and for whom
blood specimens were available for IGF-I typing, a total of
1678 subjects. This is the first genetic case association study
that uses the Rotterdam study database to investigate the
phenotype of LVH on the echocardiogram.
M mode echocardiography was performed by experienced
staff, according to recommendations of the American Society
of Echocardiography (ASE). Left ventricular mass was
determined using the Devereux modified ASE cube formula:
left ventricular mass (g) = 0.86 (1.046 [(LVED + IVS +
LVPW)3 2 (LVED)3]) + 0.6, where LVED is the left ventri-
cular end diastolic diameter, IVS is the interventricular
septum thickness, and LVPW is the left ventricular posterior
wall thickness. Left ventricular mass was indexed to body
surface area. Using predefined criteria, based on use in recent
clinical trials and ability to predict cardiovascular prognosis,
LVH was defined as having a left ventricular mass index
> 104 g/m2 in women and > 116 g/m2 in men.5 6 As
consensus concerning LVH thresholds is lacking, left ven-
tricular mass index was also divided into sex specific
quintiles.
The polymorphism under study was a cytosine–adenosine
repeat in the promoter region of the IGF-I gene. Genotyping
was performed as described elsewhere.3 Earlier, we identified
10 different alleles at this single locus in the IGF-I gene in a
sample of 900 subjects of the Rotterdam study.3 Of these
participants, 88.4% carried at least one 192 base pair allele,
corresponding to 19 cytosine–adenosine repeats, suggesting
that this is the wild type allele. The frequency of the other
nine alleles was low. Based on this observation, using the
wild type allele, our study population was divided into three
genotypes: individuals homozygous for the 192 base pair
allele (43.6%), individuals heterozygous for the 192 base pair
allele (45.6%), and non-carriers of the 192 base pair allele
(10.7%).
Hardy-Weinberg equilibrium was tested using a x2 test. We
used multivariate logistic regression to calculate odds ratios
(OR) plus 95% confidence intervals (CI) for the association
between LVH and IGF-I genotypes. An allele dose effect
model was assumed to explain differences between genotype
groups. Participants homozygous for the 192 base pair allele
served as the reference category. Allele dose–effect relation
was tested with age and sex adjusted logistic regression
(trend test). Men and women were pooled in the analyses
because there was no effect modification by sex.
RESULTS
We identified 358 cases with LVH. Genotype and allele
distributions were in Hardy-Weinberg equilibrium. Parti-
cipants with LVH were on average two years older (mean age
65 versus 63 years, t test p , 0.001), had a higher BMI, and
had diabetes mellitus and hypertension more often. Sex and
smoking did not differ significantly between participants
with or without LVH.
Table 1 shows that non-carriers of the 192 base pair allele
had a 1.5 fold increased risk of LVH compared to individuals
homozygous for the 192 base pair allele (adjusted OR 1.49,
95% CI 1.01 to 2.20). Although the frequency of LVH was not
significantly increased in heterozygotes, there was a sig-
nificant allele dose–effect relation. The odds of LVH were
multiplied by 1.2 per non-wild type allele present. Findings
were similar for the association between IGF-I genotypes and
the highest sex specific quintile versus other sex specific
quintiles of left ventricular mass index (age adjusted OR non-
carriers 1.48, 95% CI 1.001 to 2.18). In multivariate analysis
this association was, however, not significant, although the
OR remained approximately the same (OR 1.46, 95% CI 0.99
to 2.17).
DISCUSSION
In this study, non-carriers of the 192 base pair allele of a
cytosine–adenosine repeat in the promoter region of the
IGF-I gene were more susceptible to the development of LVH
than participants homozygous for the wild type allele. In
addition, there was a significant allele dose–effect relation.
Several studies have investigated the potential func-
tionality of the IGF-I polymorphism with conflicting results.
The IGF-I polymorphism has been associated with serum
IGF-I concentrations, albeit with opposite directions.2–4 7
Differences in population background (environmental and
genetic factors), age, and small sample sizes may all account
for these contradictory results. However, findings in Dutch
populations have been very consistent, strongly suggesting
Abbreviations: ASE, American Society of Echocardiography; BMI,
body mass index; IGF-I, insulin-like growth factor-I; LVH, left ventricular
hypertrophy
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that the IGF-I polymorphism can be used as a genetic
marker, at least in Dutch subjects.3 4 8 Recently, we found
that non-carriers of the 192 base pair allele had lower
circulating total IGF-I concentrations and lower body height
than carriers. The absence of this allele was significantly
associated with an increased risk of type 2 diabetes mellitus
and myocardial infarction.3 Moreover, we observed that the
normal gradual decline in circulating serum IGF-I concentra-
tions during aging was highly influenced by this polymorph-
ism in the IGF-I gene.4 Evidence suggests that IGF-I
deficiency may lead to diminished cardiac performance and
adverse remodelling in reaction to an injury to the heart.1
Confounding bias or chance may provide alternative
explanations for our results. Confounding bias is unlikely,
as we studied a homogeneous white population and potential
confounding factors did not greatly influence our results.
Chance cannot be fully excluded, since the probability that
we incorrectly rejected our null hypothesis of no association
was less than 5%.
In conclusion, non-carriers of a 192 base pair allele
polymorphism in the promoter region of the IGF-I gene are
more susceptible to the development of LVH than partici-
pants homozygous for the wild type allele. This may result
from a relative IGF-I deficiency, leading to faulty remodelling
in response to myocardial injury.
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Table 1 Association between echocardiographically determined LVH and IGF-I
genotypes
IGF-I genotype Cases* (n = 358) Controls (n = 1320) OR model 1 OR model 2`
Homozygous 192
base pair allele 145 (41%) 587 (44%) 1.00 (reference) 1.00 (reference)
Heterozygous 192
base pair allele 166 (46%) 600 (46%) 1.13 (0.88 to 1.46) 1.11 (0.86 to 1.43)
Non-carrier 192
base pair allele 47 (13%) 133 (10%) 1.50 (1.02 to 2.21) 1.49 (1.01 to 2.20)
*LVH was considered present when left ventricular mass index was >104 g/m2 in women and 116 g/m2 in men.
Adjusted for age and sex, allele effect relation p trend ,0.05
`Adjusted for age, sex, BMI, hypertension, and diabetes mellitus
Data are presented as percentages of cases or controls and as odds ratios (OR) with 95% confidence interval.
240 Scientific letter
www.heartjnl.com
 on 4 October 2006 heart.bmjjournals.comDownloaded from 
